Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859268 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
A Phase 3 study of Obesity, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
- 20
- Study locations
NCT06859268: Active Phase 3 study of Obesity, sponsored by Eli Lilly and Company.
NCT06859268 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 643 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06859268, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- ALL Medical Research, LLC - Cooper City
- Florida International Medical Research - Coral Gables
- Renstar Medical Research - Ocala
- Charter Research - Winter Park - Orlando
- Metabolic Research Institute, Inc. - West Palm Beach
Georgia
- Kubost Clinical Research - Marietta - Marietta
- North Georgia Clinical Research - Woodstock
Illinois
- Alliance for Multispecialty Research, LLC - Oak Brook
- Springfield Clinic Main Campus - Springfield
Kentucky
- Alliance for Multispecialty Research, LLC - Lexington
- L-MARC Research Center - Louisville
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
- Care Access - Lake Charles (Bayou Pines) - Lake Charles
California
- Southern California Clinical Research - Santa Ana
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
What the registry record for NCT06859268 still lists
NCT06859268 is an interventional study that assigns participants to a tested intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06859268 names 20 study sites across 12 states, led by Florida, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06859268 about?
NCT06859268 is a clinical study titled "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity". This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-...
What is the current status of trial NCT06859268?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2025-03-05. Estimated completion is 2028-04.
What conditions does trial NCT06859268 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06859268?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06859268?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859268 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06859268's enrollment target sits among peer trials
643 112th of 1053 higher than 942 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI